Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.101
Sell
RSI(14)
36.665
Neutral
STOCH(KDJ)(9,3,3)
14.358
Oversold
ATR(14)
0.404
Low Volatility
CCI(14)
-125.997
Sell
Williams %R
97.059
Oversold
TRIX(12,20)
-0.332
Sell
StochRSI(14)
0.000
Sell
Adicet Bio Inc
ACET6.300USD
-0.430-6.39%
Market hours （ET）Quotes delayed by 15 min
24.48MMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Adicet Bio Inc
Currency: USD Updated: 2026-03-27Key Insights
Adicet Bio Inc's fundamentals are relatively weak, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 129 out of 391 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 53.00.In the medium term, the stock price is expected to trend down.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Adicet Bio Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative
Adicet Bio Inc Highlights
StrengthsRisks
Adicet Bio, Inc. is a clinical-stage biotechnology company. It is engaged in advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. Its lead product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases. ADI-001 contains an anti-CD20 CAR that has a proprietary antigen-binding domain that recognizes a region of CD20 distinct from that recognized by rituximab. Its pipeline also includes ADI-270, an investigational allogeneic gamma delta CAR T cell therapy targeting CD70 via the CD27-ligand for the treatment of RCC and with potential in other solid tumor and hematological malignancy indications. Its pipeline has additional internal gamma delta T cell therapy programs in discovery and preclinical development for both hematological malignancies and solid tumors.
Overvalued
The company’s latest PE is -0.38, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 55.73M shares, increasing 8.23% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 291.28K shares of this stock.
Analyst Rating
Based on
7
analysts
Buy
Current Rating
53.000
Target Price
+687.52%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-03-27The current financial score of Adicet Bio Inc is 6.43, ranking 248 out of 391 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is high.
Score
Financials
2.04
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
7.41
Operational Efficiency
8.93
Growth Potential
6.75
Shareholder Returns
7.03
Adicet Bio Inc's Company Valuation
Currency: USD Updated: 2026-03-27The current valuation score of Adicet Bio Inc is 7.10, ranking 170 out of 391 in the Biotechnology & Medical Research industry. Its current P/E ratio is -0.38, which is -16.32% below the recent high of -0.32 and -1733.51% above the recent low of -7.00.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 129/391
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-03-27The current earnings forecast score of Adicet Bio Inc is 8.86, ranking 43 out of 391 in the Biotechnology & Medical Research industry. The average price target is 8.00, with a high of 9.00 and a low of 5.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
7
analysts
Buy
Current Rating
53.000
Target Price
+687.52%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
548
Total
6
Median
6
Average
Company name
Ratings
Analysts
Adicet Bio Inc
ACET
7
CRISPR Therapeutics AG
CRSP
29
IQVIA Holdings Inc
IQV
27
argenx SE
ARGX
26
Beigene Ltd
ONC
24
Intellia Therapeutics Inc
NTLA
24
1
2
3
...
110
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-03-27The current price momentum score of Adicet Bio Inc is 6.63, ranking 179 out of 391 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 7.59 and the support level at 5.89, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
6.672
Sell
MA10
6.864
Sell
MA20
7.107
Sell
MA50
7.394
Sell
MA100
8.197
Sell
MA200
6.036
Buy
Institutional Confidence
Currency: USD Updated: 2026-03-27The current institutional shareholding score of Adicet Bio Inc is 3.00, ranking 195 out of 391 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 45.53%, representing a quarter-over-quarter decrease of 46.82%. The largest institutional shareholder is The Vanguard, holding a total of 291.28K shares, representing 3.04% of shares outstanding, with 21.71% decrease in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Shareholder Activity
Name
Shares Held
Chg %
OrbiMed Advisors, LLC
RA Capital Management, LP
Two Sigma Investments, LP
Goldman Sachs & Company, Inc.
1
2
Risk Assessment
Currency: USD Updated: 2026-03-27The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Adicet Bio Inc is 1.29, ranking 323 out of 391 in the Biotechnology & Medical Research industry. The company's beta value is 1.59. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.
Score
Beta vs S&P 500 index
1.57
VaR
+8.00%
240-Day Maximum Drawdown
+61.30%
240-Day Volatility
+297.85%
Return
Best Daily Return
60 days
+9.16%
120 days
+19.83%
5 years
+1523.70%
Worst Daily Return
60 days
-13.32%
120 days
-14.69%
5 years
-54.29%
Sharpe Ratio
60 days
-0.96
120 days
-1.60
5 years
+0.42
Risk Assessment
Maximum Drawdown
240 days
+61.30%
3 years
+93.73%
5 years
+97.90%
Return-to-Drawdown Ratio
240 days
+18.02
3 years
+0.01
5 years
-0.08
Skewness
240 days
+15.45
3 years
+26.41
5 years
+33.78
Volatility
Realised Volatility
240 days
+297.85%
5 years
+156.57%
Standardised True Range
240 days
+7.52%
5 years
+7.91%
Downside Risk-Adjusted Return
120 days
-247.59%
240 days
-247.59%
Maximum Daily Upside Volatility
60 days
+58.58%
Maximum Daily Downside Volatility
60 days
+44.18%
Liquidity
Average Turnover Rate
60 days
+0.58%
120 days
+0.61%
5 years
--
Turnover Deviation
20 days
-38.95%
60 days
-55.90%
120 days
-54.01%
Peer Comparison
Biotechnology & Medical Research
Adicet Bio Inc
ACET
6.20 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Alkermes Plc
ALKS
8.42 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Madrigal Pharmaceuticals Inc
MDGL
8.27 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
BioCryst Pharmaceuticals Inc
BCRX
8.27 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Day One Biopharmaceuticals Inc
DAWN
8.26 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
IQVIA Holdings Inc
IQV
8.21 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
